/Investor DB

EcoR1 Capital — 2022 Investments

2 investments dated 2022 · listed companies and verified rows first · show all

Dewpoint Therapeuticsdewpointx.comin𝕏Feb 2022✓ verified

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)

Co-investorsARCH Venture PartnersGeneral CatalystSamsara BioCapital6 Dimensions CapitalInnovation EndeavorsLeaps by Bayer+6 more

Dewpointdewpointinnov.cominFeb 2022

Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.

CleantechClimate TechDeep TechNew Materials

Chiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in

Co-investorsImpact Ventures Management Pty LtdPacific Channel3E Bioventures CapitalARCH Venture PartnersGeneral CatalystLeaps by Bayer+3 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.